Can This Drug Be a Game Changer for Eli Lilly?

Eli Lilly's experimental breast cancer drug is reporting strong results in an early-stage trial. Here is what you need to know going forward.

Apr 11, 2014 at 2:30PM

Many large pharmas in the midst of the so-called "patent cliff" have chosen to turn to their development pipelines for new drugs, instead of playing the merger and acquisition game. This isn't entirely surprising given that valuations for many clinical stage biotechs have absolutely soared over the past few years, lessening their value proposition to potential acquirers. Eli Lilly & Co. (NYSE:LLY) is one of the top names facing this dilemma these days, as its top-selling drug Cymbalta has lost patent protection and Teva Pharmaceuticals launched a generic version of Evista last March. Yet, the company's pipeline has struggled to replace these top-selling drugs, with some of its most promising experimental drugs failing to meet their primary endpoints in late-stage trials over the past few years. 

Eli Lilly is thus hoping to change its fortunes with an experimental breast cancer drug known as bemaciclib. The company reported results from the drug's early stage trial last week at the American Association for Cancer Research Annual Meeting in San Diego, generating significant buzz in the process.

What perked up investors' collective attention was that patients on the drug showed a progression-free survival of around 9.1 months and 25% of patients in the trial saw their tumors shrink. What's noteworthy about these results is that the patient population in the trial had advanced disease and had stopped responding to a cavalcade of other therapies. Based on these promising early stage results, Eli Lilly has decided to advance the drug into a pivotal registration trial. Given the increasing importance of bemaciclib within Eli Lilly's pipeline, I think it's important to take a closer look at the drug's prospects for becoming the game changer the company needs moving forward.

Serving a large underserved market
Bemaciclib is targeting patients with advanced-stage, estrogen-receptor-positive breast cancer. What you need to understand is that this population makes up somewhere around 75% of the entire breast cancer market. Moreover, there are few pharmaceutical options for patients who have stopped responding to standard therapy, with many patients choosing to enroll in an ongoing clinical trial. As a result, analysts have suggested that the market size for this unmet medical need could be as high as $10 billion per year. What you should keep in mind is that Roche's (NASDAQOTH:RHHBY) wonder drug Herceptin has achieved megablockbuster status as a treatment for a much smaller cadre of breast cancer patients, namely HER2-positive patients. In short, Eli Lilly's experimental drug would probably be a blockbuster if approved.

How bemaciclib fights cancer
OK, so what does that mean? Let's take a brief walk through the science behind bemaciclib in order to understand the drug's unique approach to fighting cancer. The progression from the first cell cycle checkpoint (G1) to the DNA synthesis phase is regulated in many ways by cyclin-dependent kinases (CDKs), in particular CDK 4 and 6. What's key to understand is that many types of human cancers involve problems occurring at the transition from the first cell cycle checkpoint to the synthesis phase. By inhibiting the expression of CDKs that activate this pathway, the idea is to arrest the cell cycle, forcing it to eventually commit suicide (quite literally). Normally, cells that have problematic mutations undergo what's called "apoptosis" or programmed cell death, if G1 is delayed. Cancer cells, by contrast, proceed into the DNA synthesis phase, leading to uncontrolled proliferation and tumor formation. While we've known about this general process for decades and have been attempting to use it as a therapeutic target, our knowledge has only now progressed to the point where a drug based on this approach is feasible. Indeed, Pfizer (NYSE:PFE) and Novartis (NYSE:NVS) also have CDK 4/6 dual inhibitors indicated for advanced-stage breast cancer under development, showing the rapid growth of the field.  

Foolish wrap-up
While these early stage results are promising, we will need to wait until 2015 to 2016 for the next trial to conclude that will determine the drug's ultimate fate. By then, Pfizer could already have its competing drug Palbociclib on the market and Novartis has now advanced its drug into a late-stage trial as well. While Novartis has largely kept quiet about the progress of its drug until now, Pfizer's Palbociclib was reported to roughly double progression-free survival in its mid-stage trial, although the drug has yet to show a clinical benefit in terms of overall survival. Even so, you need to bear in mind that this is a vastly under-served market that should be able to support multiple drugs. Consequently, I believe that bemaciclib should be able to find a profitable niche, even if Pfizer and Novartis get their drugs approved first. So, this is definitely a drug in Eli Lilly's pipeline to keep close tabs on moving forward.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers